Variants in the 14q32 miRNA cluster are associated with osteosarcoma risk in the Spanish population

Idoia Martin-Guerrero, Nerea Bilbao-Aldaiturriaga, Angela Gutierrez-Camino, Borja Santos-Zorrozuoa, Vita Dolžan, Ana Patiño-Garcia & Africa Garcia-Orad

Association studies in osteosarcoma risk found significant results in intergenic regions, suggesting that regions which do not codify for proteins could play an important role. The deregulation of microRNAs (miRNAs) has been already associated with osteosarcoma. Consequently, genetic variants affecting miRNA function could be associated with risk. This study aimed to evaluate the involvement of all genetic variants in pre-miRNAs described so far in relationship to the risk of osteosarcoma. We analyzed a total of 213 genetic variants in 206 pre-miRNAs in two cohorts of osteosarcoma patients (n = 100) and their corresponding controls (n = 256) from Spanish and Slovenian populations, using Goldengate Veracode technology (Illumina). Four polymorphisms in pre-miRNAs at 14q32 miRNA cluster were associated with osteosarcoma risk in the Spanish population (rs12894467, rs61992671, rs58834075 and rs12879262). Pathway enrichment analysis including target genes of these miRNAs pointed out the WNT signaling pathways overrepresented. Moreover, different single nucleotide polymorphism (SNP) effects between the two populations included were observed, suggesting the existence of population differences. In conclusion, 14q32 miRNA cluster seems to be a hotspot for osteosarcoma susceptibility in the Spanish population, but not in the Slovenian, which supports the idea of the existence of population differences in developing this disease.

Osteosarcoma is the most common primary malignant bone tumor, mainly occurring in children and adolescents. The precise etiology of the disease remains partially unknown, but genetic factors seem to play a key role in its pathogenesis. To date, several case-control studies have reported associations of common genetic variants with osteosarcoma risk, but these studies were mainly focused on regions codifying for proteins, because results are easily interpreted biologically. However, a genome wide association study (GWAS) in osteosarcoma showed that 8 out of the 13 most significant genetic variants were located in regions with no clear functional consequence, results that are more difficult to interpret. Similar results were found in other GWAS in different cancer types, in which 44% of significant signals were described to be located in intergenic regions. All these data together suggest that regions which do not codify for proteins could play an important role in the risk of cancer, in general, and in osteosarcoma, in particular. One of the most studied non-coding RNAs are microRNAs (miRNAs), molecules of 20 nucleotides that regulate gene expression at the post-transcriptional level by binding to the 3′ untranslated region (UTR) of a target mRNA, leading to its translation inhibition or degradation. Through this mechanism, miRNAs can regulate more than half of human genes. More than 600 miRNAs have been proposed to be involved in osteogenesis regulation, so it is reasonable to think that miRNAs deregulation can be linked to osteosarcoma susceptibility. In fact, alterations of miR-34c affecting Notch signaling pathway were associated with the pathogenesis of osteosarcoma, and the deregulation of the 14q32 miRNA cluster was also linked to the...
progression and prognosis of osteosarcoma\textsuperscript{13}. Genetic variations in miRNAs can alter their function affecting their gene targets. These variants can modify the miRNA expression levels if they are located in the pre-miRNA or the miRNA-miRNA binding if they are located in the seed region. Consequently, genetic variations in pre-miRNAs affecting their function could be involved in the risk of cancer. Several works have already described polymorphisms in miRNAs associated with the susceptibility to different types of cancer\textsuperscript{13,14}. Despite all these evidences, few studies have analyzed the involvement of miRNA single nucleotide polymorphism (SNPs) in the risk of osteosarcoma so far. Although only a low number of SNPs were analyzed, significant results were found with two variations belonging to miR-34 family\textsuperscript{15,16} and with one located in mir-124a\textsuperscript{17}.

### Materials and Methods

**Patients.** The study population included 100 patients (<34 years) diagnosed of osteosarcoma at the Oncology Unit of the Department of Pediatrics of the University Clinic of Navarra (n = 74) between 1985 and 2003 and University Children's Hospital of Ljubliana (n = 26) between 1990 and 2008. Both patient cohorts were residents in Spain or Slovenia at the moment of diagnosis and had West European ancestry. Moreover, 256 healthy individuals of European origin with no previous history of cancer (n = 160 and n = 96 from Spain and Slovenia, respectively) were added (Table 1). Informed consent was obtained from all patients or their parents before sample collection. The study was approved by the Spanish Ethics Committees for Clinical Research of Euskadi (CEIC-E) (CEISH/102R/2011/GARCIA-ORAD CARLES 67/02/12) and the University of Navarra (105/2009), and by the Slovenian Ethics Committee for Research in Medicine (bilateral project BI-ES/04-05-016) and was carried out according to the Declaration of Helsinki.

### Selection of polymorphisms in miRNAs.

We selected all the pre-miRNAs including SNPs with a MAF > 0.01 in European/Caucasian populations described in the databases until May 2014. Since, on the one hand, osteosarcoma is a polygenic disease in which associated genes are not totally defined, and, on the other hand, a single miRNA can regulate several transcripts which are not completely known nowadays, we decided to analyze all polymorphic miRNAs to date. MAF > 0.01 was selected because this frequency was required to detect significant differences in our sample size.

The SNP selection was performed using miRNA SNIPer (www.integratomics-time.com/miRNA-SNIPer/), NCBI and literature review. Finally, a total of 213 SNPs in 206 pre-miRNAs were included.

### Genotyping.

Peripheral blood samples were obtained as the source of DNA from Spanish patients and all healthy controls, while in Slovenian osteosarcoma patients DNA was extracted from the areas of formalin fixed paraffin embedded (FFPE) material verified by an experienced pathologist to be representative of normal tissue. Most FFPE samples were osteogenic (>96%) from histological point of view, and all of them were primary malignancy. Genomic DNA was extracted using standard procedures\textsuperscript{19}. DNA was quantified using PicoGreen (Invitrogen Corp., Carlsbad, CA). For each sample, 400 ng of DNA were genotyped using the GoldenGate Genotyping Assay with Veracode technology according to the published Illumina protocol. Data were analyzed with Genome Studio software for genotype clustering and calling. As quality control, duplicate samples and CEPH trios (Coriell Cell Repository, Camden, NJ) were genotyped across the plates, following the Illumina recommendations.

### Statistical analysis.

The association between genetic polymorphisms and the risk of osteosarcoma was evaluated by the $\chi^2$ or Fisher’s exact test. The effect sizes of the associations were estimated by the ORs from univariate logistic regression. The most significant test among codominant, dominant, recessive and additive was used to determine the statistical significance of each SNP. The results were adjusted for multiple comparisons by the False Discovery Rate (FDR)\textsuperscript{20}. In all cases the significance level was set at 5%. Analyses were performed by

| Population (n) | Total | Controls | Cases |
|---------------|-------|----------|-------|
| Spain         | 234   | 160 (68.37) | 74 (31.62) |
| Slovenia      | 122   | 96 (78.68)  | 26 (21.31)  |

Table 1. Study population. Abbreviations: n, number of individuals; sd, standard deviation; f, female; m, male. *Sex was not available for all patients.
using R v2.11 software. χ² test was used to search for any deviation of Hardy-Weinberg equilibrium (HWE) in controls. Those SNPs that showed deviations from HWE in control population were removed from the analyses.

Bioinformatic analyses. miRNAs secondary structures prediction. The RNAfold web tool (http://rna.tbi.univie.ac.at) was used to calculate the minimum free energy secondary structures and to predict the most stable secondary structures of the miRNAs showing significant SNPs.

miRNAs expression analyses. Expression levels of miRNAs were analyzed in a series of 18 osteosarcoma cell lines (<34 years) and 4 normal bone samples, using data publicly available in GEO database under the accession GSE28423. T-tests were performed using the GEO2R web tool, applying a Benjamini and Hochberg FDR adjusted p-value cut-off of 0.05.

Gene targets selection and pathways analysis. MiRWalk database was used to select miRNA targets. Only targets predicted by at least 8 different algorithms provided by miRWalk were selected. Enriched pathway analyses of putative target genes were determined with ConsensusPath database (CPdB) (http://consensuspathdb.org/) using the over-representation analysis module. Gene list were analyzed against the default collection of KEGG, Reactome and BioCarta (http://cgap.nci.nih.gov/Pathways/BioCarta_Pathways) pathway databases. A conservative p-value cutoff (0.001) was used.

Results

Genotyping results. Genotyping analyses were performed in 100 patients diagnosed of osteosarcoma (74 Spanish and 26 Slovenian) and 256 cancer-free controls (160 and 96, respectively). Successful genotyping was obtained in 350 of 356 DNA samples (98.3%). Finally, a total of 140 SNPs were included in the association analyses, after eliminating SNPs with genotyping failures (<80%), monomorphic in the studied populations, or with deviations from HWE in controls (Table S1).

Genotype association study. We found 23 SNPs significantly associated with osteosarcoma risk: 14 SNPs in 14 miRNAs in the Spanish population and 9 SNPs in 8 miRNAs in the Slovenian. When the two populations were analyzed together, 11 SNPs at 11 miRNAs were significant.

In the Spanish population, 4 out of 14 significant SNPs were located at 14q32 region (Fig. 1). Among them, rs12894467 at miR-300 showed the most significant association value under the log-additive model (CC vs CT vs TT). The frequency of TT genotype was found to be 2.5 times higher in patients than in controls (OR = 2.01, 95% CI: 1.32–3.06; P = 0.001). With regard to the other three significant SNPs at 14q32 region, we found an increase in the risk of osteosarcoma for the genotypes AG + AA for rs61992671, CT for rs58834075 and CG for rs12879262 located at miR-412, miR-656 and miR-4309, respectively (OR = 2.21, OR = 4.98 and OR = 1.99). Other 10 SNPs showed statistically significant results (P < 0.05), 6 located in pre-miRNAs, 2 in mature miRNAs and 1 in the seed region (Table 2). After FDR correction, no SNP remained significant.
In the Slovenian population, 9 SNPs were significant. Among them, rs35613341 at miR-5189 showed the most significant association. The genotype CG for rs35613341 showed a protective effect (OR = 0.07, 95% CI: 0.01–0.59; under codominant model), association that remained significant after FDR correction. Another genotype in the same miRNA (AG + AA for rs56292801) also showed protective effect (OR = 0.25; 95% CI:0.08–0.80).

Other 7 SNPs displayed significant results (P < 0.05), 4 located in pre-miRNAs and 3 in the seed region (Table 3).

In the global analysis, a total of 11 significant SNPs were detected. Nine of them had been already found significant in the Spanish or in the Slovenian populations. Among them, 3 SNPs showed more significant and 5 less significant P values in the total population than those found in each population separately. The other 3 out of 11 significant associations detected were new (Table S2). From the total of significant SNPs observed in the Spanish

| SNP    | miRNA | Localization | Genotype | N (%) controls N = 160 | N (%) cases N = 69 | OR (CI 95%) | P      |
|--------|-------|--------------|----------|------------------------|-------------------|-------------|--------|
| 1      | rs12894467 mir-300 | 14q32 pre-miRNA | CC       | 74 (46.2) | 19 (27.5) | 2.01 (1.32–3.06) | 0.001 (add) |
|        |        |              | CT       | 71 (44.4) | 34 (49.3) |             |        |
|        |        |              | TT       | 15 (9.4)  | 16 (23.2) |             |        |
| 2      | rs356125 mir-2278 | 9q22 pre-miRNA | GG       | 140 (87.5) | 68 (98.6) | 1           |        |
|        |        |              | AG       | 20 (12.5)  | 1 (1.4)  | 0.1 (0.01–0.78) | 0.002 (codom) |
|        |        |              | AA       | 0 (0)     | 0 (0)     | 0.00 (0.00) |        |
| 3      | rs77639117 mir-576 | 4p25 pre-miRNA | AA       | 156 (97.5) | 60 (87.0) | 1           |        |
|        |        |              | AT       | 4 (2.5)    | 9 (13.0)  | 5.85 (1.74–19.71) | 0.003 (codom) |
|        |        |              | TT       | 0 (0)     | 0 (0)     | 0.00 (0.00) |        |
| 4      | rs7247237 mir-3188 | 19p13 pre-miRNA | CC       | 72 (45.3) | 23 (34.3) | 1           |        |
|        |        |              | CT       | 77 (48.4) | 31 (46.3) | 3.59 (1.49–8.66) | 0.004 (rec) |
|        |        |              | TT       | 10 (6.3)  | 13 (19.4) |             |        |
| 5      | rs60871950 mir-4467 | 7q22.1 miRNA | GG       | 35 (22.0) | 27 (39.1) | 1           |        |
|        |        |              | AG       | 83 (52.2) | 23 (33.3) | 0.44 (0.24–0.81) | 0.009 (dom) |
|        |        |              | AA       | 0 (0)     | 0 (0)     | 0.00 (0.00) |        |
| 6      | rs10505168 mir-2053 | 8q23.3 pre-miRNA | AA       | 78 (49.1) | 25 (36.2) | 1           |        |
|        |        |              | AG       | 65 (40.9) | 42 (60.9) | 2.02 (1.11–3.65) | 0.009 (codom) |
|        |        |              | GG       | 16 (10.1) | 2 (2.9)   | 0.39 (0.08–1.81) |        |
| 7      | rs61992671 mir-412 | 14q32 miRNA | GG       | 57 (35.6) | 13 (20.0) | 1           |        |
|        |        |              | AG       | 66 (41.2) | 35 (53.8) | 2.21 (1.11–4.41) | 0.018 (dom) |
|        |        |              | AA       | 37 (23.1) | 17 (26.2) |             |        |
| 8      | rs58834075 mir-656 | 14q32 pre-miRNA | CC       | 157 (98.1) | 63 (91.3) | 1           |        |
|        |        |              | CT       | 3 (1.9)   | 6 (8.7)   | 4.98 (1.21–20.55) | 0.021 (codom) |
|        |        |              | TT       | 0 (0)     | 0 (0)     |             |        |
| 9      | rs10406069 mir-5196 | 19q13 pre-miRNA | GG       | 110 (69.6) | 43 (62.3) | 1           |        |
|        |        |              | AG       | 39 (24.7) | 26 (37.7) | 1.71 (0.93–3.15) | 0.021 (codom) |
|        |        |              | AA       | 9 (5.7)   | 0 (0.0)   | 0.00 (0.00) |        |
| 10     | rs12879262 mir-4309 | 14q32 pre-miRNA | GG       | 111 (69.8) | 39 (56.5) | 1           |        |
|        |        |              | CG       | 43 (27.0) | 30 (43.5) | 1.99 (1.10–3.59) | 0.022 (codom) |
|        |        |              | CC       | 5 (3.1)   | 0 (0.0)   | 0.00 (0.00) |        |
| 11     | rs702742 mir-378h | 5q33 pre-miRNA | AA       | 117 (73.1) | 58 (86.6) | 1           |        |
|        |        |              | AG       | 41 (25.6) | 8 (11.9)  | 0.42 (0.19–0.93) | 0.022 (dom) |
|        |        |              | GG       | 2 (1.2)   | 1 (1.5)   |             |        |
| 12     | rs10422347 mir-4745 | 19p13 miRNA | CC       | 138 (87.3) | 51 (75.0) | 1           |        |
|        |        |              | CT       | 19 (12.0) | 17 (25.0) | 2.30 (1.12–4.73) | 0.025 (dom) |
|        |        |              | TT       | 1 (0.6)   | 0 (0.0)   |             |        |
| 13     | rs2289030 mir-492 | 12q22 pre-miRNA | CC       | 130 (81.2) | 60 (87.0) | 1           |        |
|        |        |              | CG       | 30 (18.8) | 6 (8.7)   | 0.00         |        |
|        |        |              | GG       | 0 (0.0)   | 3 (4.3)   | 0.00         |        |
| 14     | rs35770269 mir-449c | 5q11 seed | AA       | 61 (38.4) | 35 (50.7) | 0.64 (0.42–0.98) | 0.038 (add) |
|        |        |              | AT       | 71 (44.7) | 28 (40.6) |             |        |
|        |        |              | TT       | 27 (17.0) | 8 (11.7)  |             |        |

Table 2. Polymorphisms in miRNAs associated with osteosarcoma risk in the Spanish population. Abbreviations: OR, Odd Ratio; CI, Confidence Interval; add, additive; codom, codominant; dom, dominant; rec, recessive.
miRNAs secondary structures. We analyzed in silico the energy change (|ΔΔG|) and the secondary structures of the miRNAs with significant SNPs. In the Spanish population, 4/14 miRNAs showed drastic energy changes (>2.0 Kcal/mol) and 7 showed altered secondary structure (Fig. S1). With regard to the SNPs at 14q32 region, rs61992671 in miR-412 and rs58834075 in miR-656 induced positive energy changes which turned the miRNA hairpins from a stable to an unstable status. In the Slovenian population, 2/9 miRNAs showed energy changes >2.0 Kcal/mol and 3 displayed secondary structure changes (Fig. S2). In the global analysis, 2 of the 3 new detected miRNAs showed energy changes >2.0 Kcal/mol and all of them showed changes in the secondary structure (Fig. S3).

miRNA expression. We studied the expression levels of miRNAs of interest in osteosarcoma cell lines using the public database Gene Expression Omnibus (GEO). Out of 22 miRNAs with significant SNPs, 5 miRNAs were represented in the GSE28423 database (miR-300, miR-412, miR-492, miR-576 and miR-656). From them, mir-300 was found significantly down-regulated in osteosarcoma cell lines group (logFC = −1.545; adj-p = 0.006). The rest of miRNAs showed no significant results (p > 0.05).

Pathway analysis. We performed a pathway enrichment analysis with miRNAs of 14q32 region that modified the secondary structure, miR-412 and miR-656, using miRWalk database and ConsensusPathDB web tool. MiR-300 (the most significant SNP) was also included in pathway enrichment analysis although no remarkable results were observed (data not shown). For miR-412, we found two pathways over-represented, being both WNT signaling predicted by KEGG and Biocarta (Table S3). Regarding miR-656, only Ca2+ pathway was over-represented, with 7/55 genes targeted by this miRNA (Table S4). Of these 7 genes, 5 overlapped with WNT signaling pathway. When both miRNAs were analyzed together, 5 pathways were over-represented, being WNT signaling pathway the most significant (p = 0.000177) (Table S5), with 16/143 genes targeted by miR-412 and miR-656 (Table S6).

Table 3. Polymorphisms in miRNAs associated with osteosarcoma risk in the Slovenian population.

*Significant after FDR correction. Abbreviations: OR, Odd Ratio; CI, Confidence Interval; add, additive; codom, codominant; dom, dominant; rec, recessive.

| N | SNP      | miRNA | Localization | Genotype | N (%) controls N = 96 | N (%) cases N = 25 | OR (CI 95%) | P     |
|---|----------|-------|--------------|----------|---------------------|------------------|-------------|-------|
| 1 | rs35613341 | mir-5189 | 16q24 pre-miRNA | CC       | 49 (51.0)          | 16 (69.6)       | 1           | 0.0001* (codom) |
|   |          |       |              | GG       | 41 (42.7)          | 1 (4.3)          | 0.07 (0.01–0.59) |
|   |          |       |              | TT       | 6 (6.2)            | 6 (26.1)         | 3.06 (0.86–10.85) |
| 2 | rs4674470  | mir-4268 | 2p35 pre-miRNA | CT       | 40 (41.7)          | 1 (5.0)          | 0.07 (0.01–0.58) |
|   |          |       |              | CC       | 6 (6.2)            | 2 (10.0)         | 0.98 (0.18–5.33) |
| 3 | rs2070960  | mir-3620 | 1q42 seed    | CC       | 75 (78.9)          | 21 (87.5)        | 1           | 0.008 (codom) |
|   |          |       |              | CT       | 20 (21.1)          | 1 (4.2)          | 0.18 (0.02–1.41) |
|   |          |       |              | TT       | 0 (0.0)            | 2 (8.3)          | 0           |       |
| 4 | rs56292801 | mir-5189 | 16q24 pre-miRNA | GG       | 51 (53.1)          | 18 (81.8)        | 1           |       |
|   |          |       |              | AG       | 41 (42.7)          | 3 (13.6)         | 0.25 (0.08–0.80) |
|   |          |       |              | AA       | 4 (4.2)            | 1 (4.5)          | 1           |       |
| 5 | rs2273626  | mir-4707 | 14q11 seed   | AA       | 31 (32.3)          | 2 (8.7)          | 1           |       |
|   |          |       |              | AC       | 45 (46.9)          | 15 (65.2)        | 5.01 (1.10–22.72) |
|   |          |       |              | CC       | 20 (20.8)          | 6 (26.1)         | 1           |       |
| 6 | rs6726779  | mir-4431 | 2p16 pre-miRNA | TT       | 34 (35.8)          | 12 (63.2)        | 1           |       |
|   |          |       |              | CT       | 51 (53.7)          | 4 (21.1)         | 0.22 (0.07–0.75) |
|   |          |       |              | CC       | 10 (10.5)          | 3 (15.8)         | 0.85 (0.20–3.62) |
| 7 | rs9877402  | mir-5680 | 8q22 pre-miRNA | AA       | 88 (93.6)          | 17 (85.0)        | 1           |       |
|   |          |       |              | AG       | 6 (6.4)            | 1 (5.0)          | 0           |       |
|   |          |       |              | GG       | 0 (0.0)            | 2 (10.0)         | 1           |       |
| 8 | rs243080   | mir-4432 | 2p16 pre-miRNA | CC       | 30 (31.6)          | 12 (57.1)        | 1           |       |
|   |          |       |              | CT       | 49 (51.6)          | 5 (23.8)         | 0.35 (0.13–0.91) |
|   |          |       |              | TT       | 16 (16.8)          | 4 (19.0)         | 1           |       |
| 9 | rs3746444  | mir-499a | 20q11 seed   | TT       | 64 (66.7)          | 18 (75.0)        | 1           |       |
|   |          |       |              | CT       | 30 (31.3)          | 3 (12.5)         | 6.71 (1.06–42.73) |
|   |          |       |              | CC       | 2 (2.1)            | 3 (12.5)         | 1           | 0.044 (rec) |

(n = 14) or in the Slovenian population (n = 9), 14 did not show significant results when both population were analyzed together.
Discussion

In the Spanish population, the most interesting result was that 4 genetic variants in miRNAs belonging to the 14q32 miRNA cluster were statistically associated with the risk of osteosarcoma. From these, rs12894467 T allele at miR-300 showed the most significant result, conferring a 2.01-fold increased risk. This polymorphism was also found significant when Spanish and Slovenian populations were analyzed together, what means that it showed the same trend in both cohorts (although it was not significant in the Slovenian sample individually). The other 3 significant SNPs of the cluster in the Spanish population (rs61992671, rs58834075 and rs12879262 at miR-412, miR-656 and miR-4309, respectively) were also associated with an increased risk of osteosarcoma. Interestingly, miRNAs of this cluster were found to be under-expressed in osteosarcoma in previous studies.26,27 This miRNAs downregulation was correlated with MYC overexpression, that it is known to be related to the development of osteosarcoma.27 The miRNAs down-expression was confirmed for miR-300 in a series of osteosarcoma cell lines using GEO dataset GSE28423. Moreover, the block of 14q32 miRNAs was shown to increase the tumorigenic potential in osteoblasts, suggesting that they could work as tumor suppressors. Consequently, the loss of function of these miRNAs could be considered as a causative factor in osteosarcomagenesis.27 Supporting this idea, the bioinformatical analysis predicted that the SNPs in miR-412 and miR-656 decreased the stability of the miRNA hairpins, which has been suggested that may reduce the product of the mature miRNA.28 This reduction in miRNA levels could increase the expression of their target genes. Interestingly, pathway analyses pointed out the WNT pathway as the most over-represented pathway, which is known to play an important role in osteoblastogenesis.29 Other authors have also pointed out the involvement of WNT pathway in the development of osteosarcoma.30,31 Dysregulation of Wnt signaling pathway allows β-catenin to accumulate and translocate into the nucleus, where it activates downstream oncogenes including MYC.32 Considering these previous studies, we can hypothesize that variations in the pre-miRNAs miR-300, miR-412, miR-656 and miR-4309 could lead to their downregulation, altering the Wnt pathway which ultimately would lead to the overexpression of MYC. All these results would support the hypothesis that this region is a hotspot for the development of osteosarcoma. In fact, recent studies in early-onset osteosarcoma have shown that inherited imprinting defects in14q32 region affects gene and miRNA expression in this area, which could be associated with the pathobiology of osteosarcoma.33

Another interesting result in the Spanish population was found for rs35770269, located in the seed region of miR-449c. In this case, the T allele was observed to decrease the risk of osteosarcoma (OR = 0.64). This allele was proposed to alter the secondary structure of the miRNA (in silico), so the T allele could have a double action in the miRNA, one affecting its levels and another, the miRNA-mRNA binding. Of note, miR-449c is part of the highly conserved miR-449 cluster belonging to the miR-34 family,34 a key regulator of tumor suppression.35 SNPs in the miR-34 family have already been found involved in the risk of osteosarcoma: rs4938723 C and rs72631823 A were associated with a reduction of miR-34b and miR-34a, respectively.35,36 In addition, the underexpression of miR-34a was shown to downregulate the suppression of the proto-oncogene C-MET, promoting osteosarcoma cell proliferation and migration.36 Since miRNAs belonging to the same family usually share target genes, we can hypothesize that rs35770269 could affect the binding of miR-449c to MET.

The other 9 significant miRNA variants detected in the Spanish population also showed a putative effect on target genes with known involvement in osteosarcoma. For instance, rs77639117 T allele could increase the risk of osteosarcoma through upregulating miR-576, which in turn might downregulate RBL1, a tumor suppressor gene inactivated in 35% of osteosarcoma patients.37 The genotype rs2289030 GG could alter miR-492, affecting its target PTEN. This gene was previously shown to be downregulated in osteosarcoma cells.38-40 The T allele could have a double action in silico was proposed to alter the secondary structure of the miRNA (ΔG = -3.9 Kcal/mol), which consequently could alter the expression of its putative target gene PTEN. Consequently, the T allele was observed to decrease the risk of osteosarcoma (OR = 0.57 (95% CI: 0.39–0.83)) (Fig. S4). However, 5 SNPs decreased their significance level, what means that opposite results were detected in the two populations. This suggests that these SNPs are population specific, which indicates remarkable population differences in factors contributing to osteosarcoma risk.

In the Slovenian population, rs35613341 and rs56292801 (both located at miR-5189) showed the most remarkable results. In this case, the significant association was caused by a decrease of the percentage of heterozygotes and an increase of the percentage of homozygotes. This fact suggests the presence of a deletion in this region in which a copy number variation (CNV) (according to the database of Genomic Variations) has been described. To the best of our knowledge, this is the first time that this CNV is associated with osteosarcoma risk. Another interesting finding was observed for rs3746444 located in the seed region of the pre-miR-499. The GG genotype was associated with increased risk of osteosarcoma.41 Similar results were observed in two previous meta-analyses studying the involvement of this polymorphism in cancer susceptibility in Caucasians (although not significant).42,43 When both populations were analyzed together, a total of 6 SNPs increased the significance of association with respect to the individual analyses. These results indicate that all these SNPs showed the same trend in both populations, so they could be considered as disease markers. Among them, rs2910164 at miR-146a was previously associated with diverse types of cancer.44 This SNP was also analyzed in relation to the risk of osteosarcoma in Chinese, showing the same trend as in the population but it was not significant.45 When a meta-analysis including the three populations (Chinese, Spanish and Slovenian) was performed, a significant association was found under the dominant model (P = 0.003). The CG + CC rs2910164 genotype showed an OR = 0.57 (95% CI: 0.39–0.83) (Fig. S4). However, 5 SNPs decreased their significance level, what means that opposite results were detected in the two populations. This suggests that these SNPs are population specific, which indicates remarkable population differences in factors contributing to osteosarcoma risk.

This study has some limitations that might be addressed, such as the limited sample size. Nevertheless, considering the scarcity of the disease, we think that the number of patients included in the present study was enough to obtain valid results. Another possible weakness of the study was the relatively high failure rate in genotyping technique. However, this high chance of failure was accepted from the beginning, because despite the predicted problem with the technique, no other design option to amplify these polymorphisms was possible.
In conclusion, the most important findings of the present study indicated that SNPs located at the 14q32 miRNA cluster can be involved in the susceptibility of osteosarcoma in the Spanish population, confirming the interest of this region in the disease. Our results also confirm the existence of population differences in the risk of developing osteosarcoma. To our knowledge, this is the first study analyzing in depth so many SNPs at miRNAs in relation with the risk of osteosarcoma, which opens a promising approach to search for new susceptibility markers in this disease. New large-scale studies including functional analyses will help to validate our findings.

Ethics approval and consent to participate. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References
1. Rosenberg, A. E. et al. Conventional osteosarcoma. In: Fletcher, C. D. M., Bridge, J. A., Hogendoorn, P. C. W., Mertens, F., eds WHO Classification of Tumours of Soft Tissue and Bone. 4th edn. Lyon, France: IARC Press, 282–8 (2013).
2. Hameed, M. & Dorfman, H. Primary malignant bone tumors—recent developments. Semin Diagn Pathol 28(1), 86–101 (2011).
3. Gianferante, D. M., Mirabello, L. & Savage, S. A. Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy. Nat Rev Endocrinol 13(8), 480–491 (2017).
4. Mirabello, L. et al. A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma. BMC Cancer 11, 209 (2011).
5. Broadhead, M. L., Clark, J. C., Myers, D. E., Dass, C. R. & Choong, P. F. The molecular pathogenesis of osteosarcoma: a review. Sarcoma 2011, 959248 (2011).
6. Savage, S. A. et al. Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet 45(7), 799–803 (2013).
7. Cheetham, S. W., Gruhl, F., Mattick, J. S. & Dinger, M. E. Long noncoding RNAs and the genetics of cancer. Br J Cancer 108(12), 2419–2425 (2013).
8. Ryan, B. M., Robbins, A. I. & Harris, C. C. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 10(6), 389–402 (2010).
9. Rukov, I., Wilentz, R., Jaffe, J., Vintner, J. & Shomron, N. Pharmac-miR: linking microRNAs and drug effects. Brief Bioinform 15(4), 648–659 (2014).
10. van Wijnen, A. J. et al. MicroRNA functions in osteogenesis and dysfunctions in osteosarcoma. Curr Osteoporos Rep 11(2), 72–82 (2013).
11. Bae, Y. et al. miRNA-34c regulates Notch signaling during bone development. Hum Mol Genet 21(13), 2991–3000 (2012).
12. Kelly, A. D. et al. MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32. Genome Med 5(1), 2 (2013).
13. Xia, L. et al. Prognostic role of common microRNA polymorphisms in cancers: evidence from a meta-analysis. PLoS One 9(10), e106799 (2014).
14. Srivastava, K. & Srivastava, A. Comprehensive review of genetic association studies and meta-analyses on microRNA polymorphisms and cancer risk. PLoS One 7(11), e50966 (2012).
15. Tian, Q. et al. A causal role for circulating miR-34b in osteosarcoma. Eur J Surg Oncol 40(1), 67–72 (2014).
16. Li, H., Pei, J., Liu, H., Wang, H. & Liu, J. A polymorphism site in the pre-miR-34a coding region reduces miR-34a expression and promotes osteosarcoma cell proliferation and migration. Mol Med Rep 10(6), 2912–2916 (2014).
17. Shi, Z. W., Wang, J. L., Zhao, N., Guan, Y. & He, W. Single nucleotide polymorphism of hsa-miR-124a affects risk and prognosis of osteosarcoma. Cancer Biomark 17(2), 249–57 (2016).
18. Kosomara, A. & Griffiths-Jones, S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 42(Database issue), D68–73 (2014).
19. Sambrook, J. & Russell, D. Molecular cloning: a laboratory manual. Third edition ed. New York: Cold Spring Harbor (2001).
20. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B (Methodological) 57(1), 289–300 (1995).
21. Namáls, H. M. et al. Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One 7(10), e48086 (2012).
22. Dweep, H. & Gretz, N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods 12(8), 697 (2015).
23. Kamburov, A., Stelzl, U., Lehrach, H. & Herwig, R. The ConsensusPathDB interaction database: 2013 update. Nucleic Acids Res 41(Database issue), D793–800 (2013).
24. Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y. & Morishima, K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 45(D1), D353–D367 (2017).
25. Fabregat, A. et al. The Reactome pathway Knowledgebase. Nucleic Acids Res 44(D1), D481–7 (2018).
26. Maire, G. et al. Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Cancer Genet 204(3), 138–146 (2011).
27. Thayanithy, V. et al. Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma. Bone 50(1), 171–182 (2012).
28. Gong, J. et al. Genome-wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis. Hum Mutat 33(1), 254–63 (2012).
29. Angulo, P. et al. Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy. J Hematol Oncol 10(1), 10 (2017).
30. Chen, C. et al. Aberrant activation of Wnt/β-catenin signaling drives proliferation of bone sarcoma cells. Oncotarget 10(6(19)), 17570–83 (2015).
31. Tian, J., He, H. & Lei, G. Wnt/β-catenin pathway in bone cancers. Tumour Biol 35(10), 9439–45 (2014).
32. Zou, Y., Yang, J. & Jiang, D. Resveratrol inhibits canonical Wnt signaling in human MG-63 osteosarcoma cells. Mol Med Rep 12(5), 7221–6 (2015).
33. Shu, J. et al. Imaging defects at human 14q32 locus alters gene expression and is associated with the pathobiology of osteosarcoma. Oncotarget 7(16), 21298–314 (2016).
34. Yang, X. et al. miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRB-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev 23(20), 2388–2393 (2009).
35. Misso, G. et al. MiR-34: a new weapon against cancer? Mol Ther Nucleic Acids 3, e194 (2014).
36. Tian, Z. et al. Upregulation of micro-ribonucleic acid-128 cooperating with downregulation of PTEN confers metastatic potential and unfavorable prognosis in patients with primary osteosarcoma. Oncogenesis 7, 1601–1608 (2014).
37. Shen, L., Chen, X. D. & Zhang, Y. H. MicroRNA-128 promotes proliferation in osteosarcoma cells by downregulating PTEN. Tumour Biol 35(3), 2069–2074 (2014).
38. Gao, Y., Luo, L. H., Li, S. & Yang, C. miR-17 inhibitor suppressed osteosarcoma tumor growth and metastasis via increasing PTEN expression. Biochem Biophys Res Commun 444(2), 230–234 (2014).
39. Fairman-Williams, M. E., Guenther, U. P. & Jankowsky, E. SF1 and SF2 helicases: family matters. *Curr Opin Struct Biol* **20**(3), 313–324 (2010).
40. Qiu, M. T. *et al.* Hsa-miR-499 rs3746444 polymorphism contributes to cancer risk: a meta-analysis of 12 studies. *PLoS One* **7**(12), e50887 (2012).
41. Fan, C., Chen, C. & Wu, D. The association between common genetic variant of microRNA-499 and cancer susceptibility: a meta-analysis. *Mol Biol Rep* **40**(4), 3389–3394 (2013).
42. Peng, S. *et al.* Association of microRNA-196a-2 gene polymorphism with gastric cancer risk in a Chinese population. *Dig Dis Sci* **55**(8), 2288–2293 (2010).
43. Xu, Z., Zhang, L., Cao, H. & Bai, B. MiR-146a rs2910164 G/C polymorphism and gastric cancer susceptibility: a meta-analysis. *BMC Med Genet* **15**, 117 (2014).

**Acknowledgements**

Special thanks to Slovenian Osteosarcoma Study Group for their collaboration in sample collection. The “Slovenian Osteosarcoma Study Group” is conformed by Katja Goričar from the Institute of Biochemistry, Faculty of Medicine of Ljubljana, Viljem Kovač from the Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine of University of Ljubljana, Janez Jazbec from the Institute of Oncology Ljubljana, Janez Lamovec from the Oncology and Hematology Unit, University Children’s Hospital, University Medical Centre of Ljubljana and Prof. Vita Dolžan included in the authorship of this article. The authors would like to thank Leire Iparraguirre for her technical assistance with figures. This study was funded by the Basque Government (IT661-13, IT989-16), UPV/EHU (UFI11/35).

**Author Contributions**

A.G.O. and I.M.G. conceived and planned the experiments and N.B.A. performed the computations and B.S.Z. performed the analytic calculations for miRNA expression analysis. I.M.G. and N.B.A. verified the analytical methods. I.M.G. and N.B.A. wrote the manuscript with support from A.G.C. and A.G.O.V. D. and A.P.G. helped supervise the project. All authors provided critical feedback and helped shape the research, analysis and manuscript. All authors discussed the results and contributed to the final manuscript.

**Additional Information**

**Supplementary information** accompanies this paper at https://doi.org/10.1038/s41598-018-33712-4.

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018